Weight Gain, Obesity, and Psychotropic Prescribing

Overview

Journal J Obes

Publisher Wiley

Specialty Endocrinology

Date 2011 Feb 15

PMID 21318056

Citations 20

Authors

Nikhil Nihalani

Thomas L Schwartz

Umar A Siddiqui

James L Megna

Affiliations

Soon will be listed here.

Abstract

A majority of psychiatric medications are known to generate weight gain and ultimately obesity in some patients. There is much speculation about the prevalence of weight gain and the degree of weight gain during acute and longitudinal treatment with these agents. There is newer literature looking at the etiology of this weight gain and the potential treatments being used to alleviate this side effect. The authors undertook a comprehensive literature review in order to present epidemiology, etiology, and treatment options of weight gain associated with antipsychotics, mood stabilizers, and antidepressants.

Citing Articles

Long-term changes in adiposity markers during and after antidepressant therapy in a community cohort.

Mwinyi J, Strippoli M, Kanders S, Schioth H, Eap C, Lasserre A Transl Psychiatry. 2024; 14(1):330.

PMID: 39138155 PMC: 11322521. DOI: 10.1038/s41398-024-03032-5.

Propensity score-matching analysis comparing safety outcomes of appetite-stimulating medications in oncology patients.

Gavioli E, Burger A, Gamaleldin A, Eladghm N, Vider E Support Care Cancer. 2022; 30(7):6299-6305.

PMID: 35471615 DOI: 10.1007/s00520-022-07081-8.

Odds of fussy eating are greater among children with obesity and anxiety.

Thorsteinsdottir S, Olafsdottir A, Brynjolfsdottir B, Bjarnason R, Njardvik U Obes Sci Pract. 2022; 8(1):91-100.

PMID: 35127125 PMC: 8804926. DOI: 10.1002/osp4.548.

Increasing Psychiatrists' Role in Addressing the Cardiovascular Health of Patients With Severe Mental Illness.

Ward M Focus (Am Psychiatr Publ). 2021; 19(1):24-30.

PMID: 34483763 PMC: 8412166. DOI: 10.1176/appi.focus.20200036.

Metabolic and behavioral effects of olanzapine and fluoxetine on the model organism .

Almotayri A, Thomas J, Munasinghe M, Weerasinghe M, Heydarian D, Jois M Saudi Pharm J. 2021; 29(8):917-929.

PMID: 34408550 PMC: 8363109. DOI: 10.1016/j.jsps.2021.07.006.

References

Hollander P, Elbein S, Hirsch I, Kelley D, McGill J, Taylor T . Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998; 21(8):1288-94. DOI: 10.2337/diacare.21.8.1288. View

Vieta E, Torrent C, Garcia-Ribas G, Gilabert A, Garcia-Pares G, Rodriguez A . Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol. 2002; 22(4):431-5. DOI: 10.1097/00004714-200208000-00017. View

Bray G . Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med. 1993; 119(7 Pt 2):707-13. DOI: 10.7326/0003-4819-119-7_part_2-199310011-00016. View

Abell C, Farquhar D, Galloway S, Steven F, Philip A, Munro J . Placebo controlled double-blind trial of fluvoxamine maleate in the obese. J Psychosom Res. 1986; 30(2):143-6. DOI: 10.1016/0022-3999(86)90043-7. View

Davidson J, Abraham K, Connor K, McLeod M . Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry. 2003; 53(3):261-4. DOI: 10.1016/s0006-3223(02)01500-7. View

Masi G, Mucci M, Millepiedi S . Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol. 2002; 12(2):93-9. DOI: 10.1089/104454602760219135. View

Harvey B, Bouwer C . Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clin Neuropharmacol. 2000; 23(2):90-7. DOI: 10.1097/00002826-200003000-00006. View

Lampl Y, Eshel Y, Rapaport A, Sarova-Pinhas I . Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol. 1991; 14(3):251-5. DOI: 10.1097/00002826-199106000-00009. View

Nasrallah H, Meyer J, Goff D, McEvoy J, Davis S, Stroup T . Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006; 86(1-3):15-22. DOI: 10.1016/j.schres.2006.06.026. View

10.

Benkert O, Szegedi A, Kohnen R . Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry. 2000; 61(9):656-63. DOI: 10.4088/jcp.v61n0911. View

11.

Wetterling T . Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf. 2001; 24(1):59-73. DOI: 10.2165/00002018-200124010-00005. View

12.

Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum M . Sibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther. 1991; 50(3):330-7. DOI: 10.1038/clpt.1991.144. View

13.

Lean M . Sibutramine--a review of clinical efficacy. Int J Obes Relat Metab Disord. 1997; 21 Suppl 1:S30-6; discussion 37-9. View

14.

Paradis C, Stack J, George C, Miller M, Pollock B, Rifai A . Nortriptyline and weight change in depressed patients over 60. J Clin Psychopharmacol. 1992; 12(4):246-50. View

15.

Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G . Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002; 41(3):337-43. DOI: 10.1097/00004583-200203000-00014. View

16.

Spina E, Cavallaro R . The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opin Drug Saf. 2007; 6(6):651-62. DOI: 10.1517/14740338.6.6.651. View

17.

Tohen M, Baker R, Altshuler L, Zarate C, Suppes T, Ketter T . Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002; 159(6):1011-7. DOI: 10.1176/appi.ajp.159.6.1011. View

18.

McNeely W, Benfield P . Orlistat. Drugs. 1998; 56(2):241-9; discussion 250. DOI: 10.2165/00003495-199856020-00007. View

19.

Anderson J, Greenway F, Fujioka K, Gadde K, McKenney J, ONeil P . Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002; 10(7):633-41. DOI: 10.1038/oby.2002.86. View

20.

Meltzer H, Bobo W, Nuamah I, Lane R, Hough D, Kramer M . Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008; 69(5):817-29. DOI: 10.4088/jcp.v69n0515. View